Similar articles

• The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.

  Cohen SB. Cohen SB. Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. doi: 10.1016/j.rdc.2004.01.005. Rheum Dis Clin North Am. 2004. PMID: 15172046 Review.
• [Biological agents for therapy of rheumatoid arthritis--overview].

  Takeuchi T. Takeuchi T. Nihon Rinsho. 2005 Jan;63 Suppl 1:513-6. Nihon Rinsho. 2005. PMID: 15799409 Review. Japanese. No abstract available.
• Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.

  Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Zwerina J, et al. Arthritis Rheum. 2004 Jan;50(1):277-90. doi: 10.1002/art.11487. Arthritis Rheum. 2004. PMID: 14730626
• Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

  Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Charles P, et al. J Immunol. 1999 Aug 1;163(3):1521-8. J Immunol. 1999. PMID: 10415055 Clinical Trial.
• [When are "biologics" indicated?].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2006 Apr 27;148(17):10. MMW Fortschr Med. 2006. PMID: 16711479 German. No abstract available.